Cogent Biosciences, Inc.

COGT Healthcare Biotechnology

In the quarter to June 2026, EPS grew 1.89% and free cash flow fell 42.0%, each against the same quarter a year earlier.

29.52 0.01 +0.03%
Market cap
$5.1B
P/E
0.0×
Fwd P/E
−5.2×
Dividend yield
—
F-score
3/9
Altman Z
3.55
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
13.57 15.14 14.23 6.38
Net Debt/EBITDA
5.55 6.19 6.80 4.20
Debt/Equity
0.42 0.37 0.35 0.15
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.45) (0.54) (0.62) (0.47)
Book value per Share
3.11 3.75 4.94 2.20
Free Cash Flow
(77.64) (87.33) (79.92) (64.35)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates